维普中文期刊产品整合服务
472篇 您的检索式:作者名="STUART P"
    题名 作者 年代 出处 被引量
1在血压控制不良的高血压患者中使用数字化干预的家庭和在线血压管理:随机对照试验显示文摘HOME BP试验(The home and online management and evaluation of blood pressure)的目的是评估在初级预防中结合自我监测和自我管理的数字化干预在高血压管理中的作用。研究者纳入英国76个治疗中心经过治疗但血压控制不好(>140/90 mm Hg, 1 mm Hg=0.133 kPa)并能上网的患者622例,进行自动确定主要终点的公开随机对照试验。McMa-nus RJ Little P Stuart B Morton K Raftery J Kelly J Bradbury K Zhang J Zhu S Murray E May CR Mair FS Michie S Smith P Band R Ogburn E AllenJ Rice C Nut-tall J Williams B Yardley L 陈嘉睿(译) 叶鹏(审校) 2021中华高血压杂志2021,29,5:15
2加强流行病学中观察性研究报告质量(STROBE)声明:观察性研究报告规范显示文摘很多生物医学研究都是观察性的。但对这类研究的报告却通常不完整,从而限制了对其优缺点及普适性的评价。“加强流行病学中观察性研究报告质量(STROBE)”工作组针对一篇完整明确的观察性研究报告应包括的内容提供了一套建议。建议涵盖了流行病学研究的三种主要设计类型:队列设计、病例对照设计和横断面设计。2004年9月,我们召开了为期2天的研讨会,与会的方法学专家、研究人员和期刊编辑共同起草了一份观察性研究报告应纳入的条目清单草案。此后,又通过协调小组数次会议及与有关人员电子邮件讨论等对该草案进行了修改,纳入了经验性证据和方法学方面的意见。通过研讨会及之后反复的咨询和修订,我们制定出了一个包含22个条目的清单(STROBE声明),分为论文的题目、摘要、引言、方法、结果和讨论等部分。其中18个条目适用于所有三种主要的观察性研究设计,其余4个条目则专门用于队列、病例一对照或横断面设计。详细的解释和示范文件已另行发表,在《公共科学图书馆一医学》(PLoS Medicine)、《内科学年报》(Annalsof Internal Medicine)和《流行病学》(Epidemiology)的网站可以免费获得。我们希望STROBE声明能有助于改善观察性研究报告的质量。Erikvon Elm Douglas G Altman Matthias Egger Stuart J Pocock Peter C G tzsche Jan P Vandenbroucke 赵乐(译) 邹光勇(审) 杜怀东(审) 2008世界临床医学2008,2,1:12
3Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial显示文摘Michael P Manns John G McHutchison Stuart C Gordon Vinod K Rustgi Mitchell Shiffman Robert Reindollar Zachary D Goodman Kenneth Koury Mei-Hsiu Ling Janice K Albrecht 2001The Lancet2001,,9286:4
4Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial显示文摘Michael P Manns John G McHutchison Stuart C Gordon Vinod K Rustgi Mitchell Shiffman Robert Reindollar Zachary D Goodman Kenneth Koury Mei-Hsiu Ling Janice K Albrecht 2001The Lancet . 2001 (9286)2001,,9286:4
5Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial显示文摘Michael P Manns John G McHutchison Stuart C Gordon Vinod K Rustgi Mitchell Shiffman Robert Reindollar Zachary D Goodman Kenneth Koury Mei-Hsiu Ling Janice K Albrecht 20012001 (9286)2001,,9286:4
6The treatment of traumatic optic neuropathy显示文摘Leonard A Levin Roy W Beck Michael P Joseph Stuart Seiff Raymond Kraker 1999Ophthalmology1999,,7:2
7Outbreaks of virulent infectious bursal disease in East Anglia显示文摘Chettle N J Stuart J C Wyeth P J 1989Veterinary Record1989,125,:2
8A randomized clinical trial of induction therapy with OKT3 in kidney transplantation 显示文摘Norman D J Kahana L Stuart F P 1993Transplantation1993,55,1:2
9Doped graphene/carbon black hybrid catalyst giving enhanced oxygen reduction reaction activity with high resistance to corrosion in proton exchange membrane fuel cells显示文摘Nitrogen doping of the carbon is an important method to improve the performance and durability of catalysts for proton exchange membrane fuel cells by platinum–nitrogen and carbon–nitrogen bonds. This study shows that p-phenyl groups and graphitic N acting bridges linking platinum and the graphene/carbon black(the ratio graphene/carbon black = 2/3) hybrid support materials achieved the average size of platinum nanoparticles with(4.88 ± 1.79) nm. It improved the performance of the lower-temperature hydrogen fuel cell up to 0.934 W cm^(-2) at 0.60 V, which is 1.55 times greater than that of commercial Pt/C. Doping also enhanced the interaction between Pt and the support materials, and the resistance to corrosion, thus improving the durability of the low-temperature hydrogen fuel cell with a much lower decay of 10 mV at 0.80 A cm^(-2) after 30 k cycles of an in-situ accelerated stress test of catalyst degradation than that of 92 mV in Pt/C, which achieves the target of Department of Energy(<30 mV). Meanwhile,Pt/Nr EGO_(2)-CB_(3) remains 78% of initial power density at 1.5 A cm^(-2) after 5 k cycles of in-situ accelerated stress test of carbon corrosion, which is more stable than the power density of commercial Pt/C, keeping only 54% after accelerated stress test.Zhaoqi Ji Jianuo Chen María Pérez-Page Zunmin Guo Ziyu Zhao Rongsheng Cai Maxwell T.P.Rigby Sarah J.Haigh Stuart M.Holmes 2022Journal of Energy Chemistry2022,31,5:2
10Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia 显示文摘Mohamed F Marchettini P Stuart OA 2003Ann Surg Oncol2003,10,4:1
11Transgenic zebrafish as sentinels for aquatic pollution显示文摘Carvan M J Dalton T P Stuart G W 2000Ann N Y Acad Sci2000,919,:1
12Nonresurfaced patella in total knee arthroplasty 显示文摘Smith SR Stuart P Pinder IM 1989J Arthroplasty1989,4,:1
13A novel method for the growth of Silicalite membranes on stainless steel supports显示文摘Stuart H Christian M M Richard P 1999Chem Mater1999,11,:1
14Housing wealth,fi-nancial wealth,and consumption:New evidence from microdata显示文摘Raphael B Stuart G Gary P 2009Regional Science and Urban Economics2009,,:1
15Self- consistent field theory of protein adsorption in a non- Gaussian polyelectrolyte brush显示文摘Biesheuvel P M Leermakers F A M Stuart M A C 2006Physical Review E2006,73,01:1
16High precision sampling for chromatographic separation显示文摘Barry E B Stuart P C Leitner J E 1973Anal Chem1973,45,14:1
17Impact of Entrepreneurial Management Experience on Early Performance 显示文摘STUART R W ABETTI P A 1990Journal of Business Venturing1990,5,3:1
18The competence of top team members: A frame-work for successful performance 显示文摘Thompson J E Stuart R Lindsay P R 1996Journal of Managerial Psychology1996,11,3:1
19Early events in integrin ανβ6-mediated cell entry of foot-and-mouth disease virus显示文摘STEPHEN B STUART C MONAGHAN P 2005J Virol2005,79,13:1
20Amoxicillin for acute lower- re- spiratory -tract infection in primary care when pneumonia is not sus- pected : a 12 - country, randomised, placebo - controlled trial 显示文摘Little P Stuart B Moore M 2013Lancet Infect Dis2013,13,2:1
返回顶部 每页显示:
共24页 首页 上一页 第1页 下一页 末页 /24 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费